as of 10-06-2026 3:36pm EST
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including covid. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens and neoantigens; monospecific and bispecific antibodies; and antibody-drug conjugates, or ADCs. Comirnaty, its Pfizer-partnered covid vaccine, is its first commercialized product.
| Founded: | 2008 | Country: | Germany |
| Employees: | N/A | City: | N/A |
| Market Cap: | 24.7B | IPO Year: | 2019 |
| Target Price: | $115.73 | AVG Volume (30 days): | 792.4K |
| Analyst Decision: | Buy | Number of Analysts: | 20 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | N/A | EPS Growth: | N/A |
| 52 Week Low/High: | $79.81 - $124.00 | Next Earning Date: | 11-03-2026 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | -37.04% | Revenue Growth (next year): | 0.20% |
| P/E Ratio: | N/A | Index: | N/A |
| Free Cash Flow: | N/A | FCF Growth: | N/A |
Machine learning model trained on 25+ technical indicators
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Chief Executive Officer
Avg Cost/Share
$96.81
Shares
21,000
Total Value
$2,032,995.30
Owned After
87,209
SEC Form 4
Chief Executive Officer
Avg Cost/Share
$97.23
Shares
72,000
Total Value
$7,000,646.40
Owned After
87,209
SEC Form 4
Chief Executive Officer
Avg Cost/Share
$98.12
Shares
32,000
Total Value
$3,139,849.60
Owned After
87,209
SEC Form 4
Chief Executive Officer
Avg Cost/Share
$98.26
Shares
34,000
Total Value
$3,340,809.40
Owned After
87,209
SEC Form 4
Chief Executive Officer
Avg Cost/Share
$98.47
Shares
34,000
Total Value
$3,347,918.80
Owned After
87,209
SEC Form 4
Chief Executive Officer
Avg Cost/Share
$98.69
Shares
27,000
Total Value
$2,664,581.40
Owned After
87,209
SEC Form 4
Chief Executive Officer
Avg Cost/Share
$98.99
Shares
39,000
Total Value
$3,860,660.70
Owned After
87,209
SEC Form 4
Chief Executive Officer
Avg Cost/Share
$99.40
Shares
30,000
Total Value
$2,982,081.00
Owned After
87,209
SEC Form 4
Chief Executive Officer
Avg Cost/Share
$100.72
Shares
46,000
Total Value
$4,633,037.20
Owned After
87,209
SEC Form 4
Chief Executive Officer
Avg Cost/Share
$97.81
Shares
33,000
Total Value
$3,227,720.10
Owned After
87,209
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Sahin Ugur | BNTX | Chief Executive Officer | Oct 6, 2026 | Sell | $96.81 | 21,000 | $2,032,995.30 | 87,209 | |
| Sahin Ugur | BNTX | Chief Executive Officer | Oct 5, 2026 | Sell | $97.23 | 72,000 | $7,000,646.40 | 87,209 | |
| Sahin Ugur | BNTX | Chief Executive Officer | Sep 30, 2026 | Sell | $98.12 | 32,000 | $3,139,849.60 | 87,209 | |
| Sahin Ugur | BNTX | Chief Executive Officer | Sep 29, 2026 | Sell | $98.26 | 34,000 | $3,340,809.40 | 87,209 | |
| Sahin Ugur | BNTX | Chief Executive Officer | Sep 28, 2026 | Sell | $98.47 | 34,000 | $3,347,918.80 | 87,209 | |
| Sahin Ugur | BNTX | Chief Executive Officer | Sep 25, 2026 | Sell | $98.69 | 27,000 | $2,664,581.40 | 87,209 | |
| Sahin Ugur | BNTX | Chief Executive Officer | Sep 24, 2026 | Sell | $98.99 | 39,000 | $3,860,660.70 | 87,209 | |
| Sahin Ugur | BNTX | Chief Executive Officer | Sep 23, 2026 | Sell | $99.40 | 30,000 | $2,982,081.00 | 87,209 | |
| Sahin Ugur | BNTX | Chief Executive Officer | Sep 22, 2026 | Sell | $100.72 | 46,000 | $4,633,037.20 | 87,209 | |
| Sahin Ugur | BNTX | Chief Executive Officer | Sep 21, 2026 | Sell | $97.81 | 33,000 | $3,227,720.10 | 87,209 |
See how BNTX stacks up against similar companies in the market
Enhance your trading experience with our free tools
The information presented on this page, "BNTX BioNTech SE - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.